Trial Outcomes & Findings for Zonisamide in the Treatment of Essential Tremor (NCT NCT00616343)
NCT ID: NCT00616343
Last Updated: 2014-07-17
Results Overview
PI has left the institution and we are unable to accurately assess the data from the remaining records.
Recruitment status
TERMINATED
Study phase
NA
Target enrollment
9 participants
Primary outcome timeframe
4 weeks
Results posted on
2014-07-17
Participant Flow
Participant milestones
| Measure |
Zonisamide
Zonisamide: 100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
|
|---|---|
|
Overall Study
STARTED
|
9
|
|
Overall Study
COMPLETED
|
9
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Zonisamide in the Treatment of Essential Tremor
Baseline characteristics by cohort
| Measure |
Zonisamide
n=9 Participants
Zonisamide: 100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
|
|---|---|
|
Age, Continuous
|
66.1 Years
STANDARD_DEVIATION 16.33078 • n=5 Participants
|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
4 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
5 Participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
9 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 4 weeksPI has left the institution and we are unable to accurately assess the data from the remaining records.
Outcome measures
Outcome data not reported
Adverse Events
Zonisamide
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place